Enveric Biosciences (ENVB)
Develops non-hallucinogenic neuroplastogenic medicines for psychiatric and neurological disorders.
Something off on this page? Send us feedback.
Develops preclinical, non-hallucinogenic neuroplastogenic small molecules for psychiatric and neurological disorders, led by EB-003. With no approved products or operating revenue, its model pairs internal drug development with out-licensing, milestones, and royalties.
Develops non-hallucinogenic neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. Its primary internal program, EB-003 in the EVM301 Series, is a DMT derivative designed to engage serotonin receptors and promote neuroplasticity without hallucinogenic effects. The Psybrary platform combines chemistry and synthetic biology to generate, synthesize, screen, and patent psychedelic-inspired structures.
Operates from Cambridge with discovery centered in Calgary and support from academic partners, scientific advisers, CROs, and CMOs. It has no approved product or operating revenue, while its prospective model combines internal development with out-licensing, milestones, and royalties. EB-003 remains preclinical and depends on IND-enabling work, regulatory clearance, clinical trials, manufacturing, and FDA approval; related research also depends on controlled-substance licensing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $8.3M · Total debt $0 · Total assets $8.9M · Shareholders' equity $8.1M
- Revenue
- $0
- Operating income
- −$3.0M
- Net income
- −$3.0M
No dividends on record.
| Institutions11 holders · as of Mar 31, 2026 | 9.21% | 55.0K shares | |
| Insiders8 holders · as of Dec 30, 2025 | 26.98% | 161.1K shares | |
| Strategic holders1 holder · as of Aug 14, 2026 | 67.85% | 405.1K shares | |
| Adds to | 104.04% |
597.0K company shares as of Aug 31, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (4.48M in the company's Sep 3, 2026 report, 597.0K elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 104.04%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Armistice Capital, LLCStrategic | 67.85% | 405,092 | 13Gfiled Aug 14, 2026 ↗ |
Joseph Edward TuckerInsiderdirector, officer: Chief Executive Officer | 11.98% | 71,507 | Form 4filed Dec 30, 2025 ↗ |
Kevin Michael CoveneyInsiderofficer: Chief Financial Officer | 7.94% | 47,413 | Form 4filed Dec 30, 2025 ↗ |
Geode Capital Management, LLCInstitution | 5.38% | 32,149 | 13Fas of Mar 31, 2026 |
Advisorshares Investments LLCInstitution | 2.84% | 16,974 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- Helus Pharma
Broadest listed peer in serotonergic mood-disorder programs.
- Definium Therapeutics
Late-stage psychedelic contender in depression and anxiety.
- Compass Pathways (ADR)
Late-stage psilocybin contender in treatment-resistant depression.
- AbbVie
Well-funded MDD challenger with a Phase 2 short-acting psychedelic.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Enveric Biosciences | $1.38 | −2.47% | $859.7K | — | — | — | — |
| Helus Pharma | $12.12 | +1.44% | $740.7M | — | — | — | — |
| Definium Therapeutics | $39.09 | +0.41% | $5.16B | — | — | — | — |
| Compass Pathways (ADR) | $13.21 | −0.11% | $1.79B | — | — | — | — |
| AbbVie | $261.07 | −0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Median | 73.7 | 17.2 | 7.2 | +10.2% |